NCT05415670View on ClinicalTrials.gov

Benign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing(GM-seq)

CompletedOBSERVATIONAL
Enrollment

158

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

August 1, 2025

Conditions
Pulmonary Nodule, SolitaryWhole-genome Methylation Sequencing
Interventions
DIAGNOSTIC_TEST

Whole-genome Methylation Sequencing(GM-seq)

A Whole-genome Methylation detection method, which can analyze the genome-wide, single base resolution methylation of tissue / blood samples, and is used to develop a benign and malignant classification model for Pulmonary Nodule.

Trial Locations (2)

100028

Emergency general hospital, Beijing

100730

Beijing hospital, Beijing

All Listed Sponsors
collaborator

Beijing Hospital

OTHER_GOV

collaborator

Emergency General Hospital

OTHER

lead

Geneplus-Beijing Co. Ltd.

INDUSTRY

NCT05415670 - Benign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing(GM-seq) | Biotech Hunter | Biotech Hunter